AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR-T Cell therapy
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR-T
Description: CAR-T Cell therapy
Study NCT06695013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bridging radiotherapy
Description: For patients in the experimental group, the decision regarding radiotherapy will depend on whether the specific lesions are suitable.
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3-4W
Study NCT06695013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg IV Q3-4W
Study NCT06772649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression sleeve
Description: The Bauerfeind compression sleeve is a fabric sleeve designed to support the ankle during movement. It's made of a compressive knit material that increases sensorimotor feedback, enhances blood circulation, and stimulates metabolism. The design helps reduce ligament strain, activates the foot's stabilizing muscles more quickly, and improves joint coordination.
Study NCT05551104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nifedipine
Description: Administration of oral nifedipine to control postpartum hypertension.
Study NCT05551104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Labetalol
Description: Administration of oral labetalol to control postpartum hypertension.
Study NCT06517771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online aerobic exercise
Description: Before starting the online aerobic exercises, for general warm-up, two minutes of walking, one minute of marching, and ten repetitions of bilateral reciprocal shoulder flexion-extension, shoulder horizontal abduction-adduction, and unilateral shoulder flexion and circling exercises were performed. For the upper extremity, full elbow extension with shoulder retraction in full shoulder flexion (Exercise V), elbows 90 degrees flexion with shoulder retraction in 90 degrees abduction (Exercise U), and full elbow flexion with shoulder extension of about 30 degrees (Exercise W) were performed. Standing hip abduction-extension, elevation on tiptoe, standing-sitting from a chair with hands on shoulders, squatting, tandem walking, and standing on one leg exercises were performed in the lower extremities. Gastrocnemius, hamstring, and shoulder posterior and inferior capsule stretching exercises were conducted as cooling exercises.
Study NCT06581965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short duration prophylaxis
Description: Only during hospitalization: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guideline Antitrombotisch beleid. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use (same type as used for control group).
Study NCT06581965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher intensity and longer duration prophylaxis
Description: The use of any thrombocyte aggregation inhibitors should be discontinued 5 days prior to surgery. Day 0-2: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.~Day 3: Apixaban 5mg b.i.d., continued until 6 weeks after surgery, conditional on the fact that no active bleeding of the surgical wound can be observed. In case of active bleeding, the prophylactic dose of thrombosis prophylaxis is continued. Thereafter, in case no active bleeding has been observed for 24 hours, the 5mg b.i.d. apixaban treatment will be started.~The 5mg b.i.d. apixaban dose will be adjusted to 2.5mg b.i.d. in case of an impaired kidney function (defined as eGFR 10-30ml/min).
Study NCT06581965 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
Study NCT06581965 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: 4 weeks: any type of LMWH or DOAC in a prophylactic dose as approved by the Dutch guidelines. First dose of LMWH within 6-24h following surgery. First dose of apixaban within 12-24h following surgery. First dose of rivaroxaban 6-10h following surgery. First dose of dabigatran within 1-4h following surgery. The applied type of anticoagulant is according to the local standard use.
Study NCT06548607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study NCT05284240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auryon Laser System
Description: The Auryon BTK Study is a prospective, single arm multicenter study evaluating the safety and procedural effectiveness of the Auryon laser in treating infrapopliteal disease in patients with critical limb ischemia and claudication.~The primary exposure of interest for this study is the use of the AURYON system for atherectomy.
Study NCT05056493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caremap app
Description: The Caremap app is intended for organizing and tracking patient-reported health insights over time and sharing those trends and patient-centered goals with their providers, not for urgent/emergent clinical communication. Information shared with providers through the app will be used for clinical care at the discretion of their provider. Use of the app to share information and health insights will not replace usual, existing channels for patient-provider communication (e.g., MyChart, phone calls, email, pager, etc.).
Study NCT05317390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DystoniaNet-based diagnosis of isolated dystonia
Description: DystoniaNet will be used for the diagnosis of dystonia and its differential diagnosis from other neurological and non-neurological disorders mimicking symptoms of dystonia
Study NCT04505371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Intervention for Smokers with HIV
Description: WISH is delivered remotely by mobile phone (voice and text message). WISH addresses both smoking and a number of other personally relevant health behaviors (such as treatment engagement, medication adherence, stress and mood management, social support, alcohol use, etc.), making it relevant and engaging to all, not just those ready to stop smoking. For those not yet ready to quit, WISH is designed to build and strengthen motivation and self-confidence for quitting, while smokers also work on other personal health goals.~Once ready to quit smoking, participants receive evidence-based cognitive-behavioral counseling and encouragement to access nicotine replacement therapy (NRT) or other appropriate pharmacotherapy through usual care VA procedures. Medications will not be prescribed or dispensed by the study.
Study NCT04163536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
Study NCT04163536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
Study NCT05001776 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation
Description: Laser ablation of the great saphenous vein close to sapheno-femoral junction
Study NCT05001776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Sodium
Description: Fondaparinux sodium for 7 days or 45 days
Study NCT05720962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uninterrupted accompanying support
Description: When the participants in the experimental group are taken to the delivery unit, when the neck dilation is 4 cm, a person they want will be taken with them to support them.~Afterwards, the pain status and satisfaction of the participants will be questioned when it is 4 cm, 6 cm, 8 cm and 10 cm.
Study NCT06313749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Micro Sclerostomy Device
Description: During this clinical trial, the Minimally Invasive Micro Sclerostomy (MIMS®) procedure will be performed by investigators using the proprietary MIMS® device developed by Sanoculis Ltd.
Study NCT05728762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel LEDs
Description: LEDs with a continuous spectrum of 430-780 nm.
Study NCT04358913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR scan with the Alberta linac-MR P3 system
Description: Single MR imaging session to develop and optimize the necessary MR sequences on the Alberta linac-MR P3 system to allow for MR-guided radiotherapy.
Study NCT05406245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate drinking
Description: Administration of carbohydrate fluid
Study NCT05287724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 1,500 mg twice daily for seven days
Study NCT05287724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken twice daily for seven days
Study NCT05641324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANV419
Description: ANV419 administered by intravenous (IV) infusion
Study NCT05254587 — intervention group
Intervention type: DEVICE
Intervention: IOLMASTER 700 TK
Description: 4 different intraocular lens (IOL) calculation methods (Haigis TK, ASCRS calculator, Barrett True K Classic K, Barrett True K TK) will be performed using the preoperative biometry and post operative refraction data.
Study NCT06074718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pricking therapy and wheat grain moxibustion
Description: pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
Study NCT06074718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pricking therapy and wheat grain moxibustion
Description: pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points
Study NCT05641324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide with low-dose dexamethasone
Description: Lenalidomide and dexamethasone administered orally
Study NCT05641324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab administered by subcutaneous injection
Study NCT05251519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Derotation taping with Kinesio Tex is applied to the patients through a pediatric physiotherapist.
Study NCT04954703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique of gluteus maximus and tensor fascia lata
Description: it is used for lengthening of hypertonic muscles for relief of pain and range of motion.Position of patient is supine lying and therapist is at side of table .The patient leg is fully adducted to stretch IT band and then patient attempts to abduct the leg against resistance contracting the muscles being stretched at approximately 25% of maximum effort for 10 seconds. They then relax and the therapist lengthen it.
Study NCT04954703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release of iliotibial band syndrome
Description: Myofascial release of IT band Syndrome. Therapist fingers track up and down your ITB with fingertips to find the most tender spots and use a tennis ball to apply small, circular, light release in those places.
Study NCT04691557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: YoungAsthma is a web-based mobile health app has been developing user-focused for adolescents with asthma and evidence-based by the research team. It is the integrated version of the knowledge content to software that enables effective management of asthma by strengthening the interaction between adolescents and healthcare professionals.
Study NCT04691557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Adolescents in the control group, an asthma training covering also individualized specific conditions is provided by specialist training nurse for 15-30 minutes in the nursing room of the outpatient clinic for all children. In this nursing intervention that is only one-off and consist face-to-face training with adolescents video and visual materials included in the routine of the outpatient clinic for the use of devices and drugs are used.
Study NCT06310538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kou sha
Description: Kou sha is one of the most important external treatments in traditional Chinese medicine. By using the kou sha to pat on specific parts of the body or acupuncture points, light or heavy slapping is carried out to produce strong vibrations to relax the meridian qi, promote local blood circulation, and achieve the effect of blood circulation and blood stasis, detoxification and evil spirits.
Study NCT06310538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hongjin Xiaojie Capsules
Description: The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
Study NCT05177224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound acquisitions to define liner position during movements
Description: Ultrasound acquisition of the dual mobility cup will be performed before and after movement. Acquisitions will be performed on the groin area.~Movement will be performed 3 times and are:~* Walking~* Knee-bending~* Standing up~* Stair climbing Movement acquisition of the lower limb will be performed using reflective markers placed on the skin. The movements will be recorded using motion capture system (infrared cameras). The load applied by the patients on the ground when doing these movements will be recorded with a force plate.
Study NCT04748822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaires
Description: The Alcohol Quality of Life Scale (AQoLS) will be completed at baseline and at 6-month follow-up. Alcohol status (relapse/abstinence) will be assessed at 6 months.
Study NCT05479006 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.
Study NCT05027100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Tislelizumab Irinotecan
Description: Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W
Study NCT05729646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Perioperative Toripalimab, 240 mg IV infusion
Study NCT05479006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (high- definition)
Description: 20 minutes, 2 mA stimulation.
Study NCT05729646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Study NCT05729646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin (130 mg/m2) infusion as perioperative chemotherapy
Study NCT05729646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study NCT05729646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1 orally intake as perioperative chemotherapy
Study NCT05251519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Conventional rehabilitation program is applied to the patients through a pediatric physiotherapist
Study NCT06394700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written exposure therapy
Description: Written Exposure Therapy (WET) is a manualized exposure-based therapy involving five sequential weekly individual sessions. Each session lasts approximately 40 minutes except the first, which is one hour. In the initial session, the therapist explains the treatment rationale and guides the participant to write about their traumatic experience uninterrupted for 30 minutes. Subsequent sessions start with a brief discussion about the previous session's writing, followed by another 30-minute writing session, concluding with a short check-in. There is no homework between sessions.
Study NCT04964557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study NCT04964557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study NCT06394700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy plus Mindfulness-Based App (WET + MBA)
Description: WET + MBA combines the standard WET protocol with the addition of a mindfulness practice facilitated through a mobile app called Now Meditation. This app is among the most downloaded mindfulness apps in China, used to help manage symptoms of insomnia commonly comorbid with PTSD. Participants are instructed to engage in daily mindfulness exercises according to the app's 7-Day Basic Meditation program and continue practicing mindfulness throughout the duration of the therapy. This is intended to supplement the therapeutic effects of WET by providing tools to manage insomnia and potentially enhancing the therapeutic process by fostering greater mindfulness and relaxation.
Study NCT06394700 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal Contact Control (MCC)
Description: MCC contains weekly phone calls from a study therapist to monitor their status and provide support as needed, without introducing any specific therapeutic interventions. These calls are brief, generally lasting between 10 to 15 minutes, and are strictly for the purpose of engagement and safety monitoring rather than therapeutic intervention.
Study NCT06085118 — intervention group
Intervention type: OTHER
Intervention: Pepticate® Syneo®
Description: Introduction of the nutritional treatment Pepticate® Syneo® (high protein hydrolysate), as a foodstuff for special medical purposes (product already available on the market).
Study NCT05362838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
Study NCT05362838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
Study NCT06248229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dyanavel XR
Description: Dosing will begin the morning following Visit 2. Subjects in the active group will begin the study on 5 mg of Dyanavel XR. Subjects will be advised to take one capsule each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.